F actors that initiate or sustain syndromes associated with acute myocardial ischemia in humans have not been defined completely. Speculation on the mechanisms responsible for the development of these syndromes has included consideration of certain humoral mediators whose effects may be augmented at sites of coronary endothelial injury and fixed atherosclerotic stenoses.1-3 Several lines of experimental data indicate that serotonin may be such a mediator. First, serotonin is released by activated platelets, and a close relation between platelet aggregation, thrombus formation, and the release of large amounts of serotonin into the coronary circulation has been established in a canine model. 4, 5 Second, serotonin concentrations are elevated at sites of fixed coronary artery obstruction and endothelial injury in certain experimental models, and the vasoconstrictor properties of serotonin are potentiated at the sites of endothelial injury.5-7 Finally, transient cyclic coronary blood flow alterations that can be established in severely stenosed canine coronary arteries with superimposed endothelial injury are prevented by a serotonin receptor antagonist and reestablished by the administration of serotonin. 5, 8, 9 Serotonin may have similar effects in humans and, thus, be an important mediator of certain acute ischemic syndromes. Therefore, the purpose of this study was to evaluate alterations in serotonin concentrations in the coronary circulation of humans and to determine whether or not there are any specific clinical or anatomic factors associated with increased transcardiac serotonin concentrations.
Materials and Methods

Patients
Blood samples for serotonin analyses were collected from the central aorta and coronary sinus in 52 patients (51 men, one woman) referred for cardiac catheterization and coronary arteriography. These patients were randomly selected from the total population referred to the laboratory for the evaluation of severe, limiting angina, or noncoronary conditions, such as valvular heart disease or atypical chest pain that could not be evaluated noninvasively. Therefore, the patients selected for study had either a high or low likelihood of coronary artery disease. Patients with acute (< 24 hours) myocardial infarction and those in whom the catheterization procedure began after 1:00 PM were excluded. The latter criterion was necessary because of the time required for processing the serotonin samples after the procedure.
Thirty-nine patients (mean age, 59 ± 9.5 years) had coronary artery disease defined as the presence of at least one epicardial coronary artery having a luminal diameter narrowing of greater than 50% (Table 1) . No patient in this group has stenoses confined to the right coronary artery. Six patients had disease of one vessel (five patients had stenosis in the left anterior descending; one patient had stenosis in the large circumflex marginal vessel), 18 had disease of two vessels, and 15 had disease of all three coronary arteries. Thirteen patients (mean age, 56 ± 10.1 years) had no significant coronary artery stenoses; eight had no coronary lesions detectable by angiography, two had a single coronary artery lesion less than 50% luminal diameter narrowing in a secondary branch of a major artery, and three had lesions less than 30% luminal diameter narrowing in a major artery. All patients were evaluated before coronary arteriography, and their symptoms were classified as either stable or unstable. Stable symptoms were defined by the presence of exertional chest pain typical for angina pectoris with symptoms remaining at a constant frequency and severity for the preceding 2 months. Some patients with stable angina had a variable threshold for their symptoms10 and occasional episodes of rest or nocturnal pain, but these episodes were infrequent and did not increase in number before the catheterization. Unstable symptoms were defined by the presence of episodes of typical ischemic chest pain with the frequency or severity of the pain or both increasing during the preceding 2 months. Patients with the recent onset of angina (< 2 months in duration), recent prolonged episodes of angina (>30 minutes) without infarction, and those with angina developing after a recent (<4 weeks) myo- The femoral vein and artery were sequentially entered and cannulated with hemostatic sheaths. Through the femoral vein sheath, a 6.5F, 100-cm Simmons II polyurethane catheter (Torcon Green Cook, Bloomington, Indiana) was advanced over a guidewire into the right atrium. After removal of the guidewire and flushing with a small amount of saline containing heparin 2 units/ml, this catheter was positioned in the coronary sinus by a method previously described." The shape of this catheter allows it to be positioned easily in the coronary sinus with its tip resting approximately 2 cm within the coronary sinus. Respiration causes minimal movement of this catheter, and the position was checked often by fluoroscopy to ensure stability. In a similar fashion, a 110-cm 8F polyurethane pigtail catheter was advanced through the femoral arterial sheath over a guidewire. After removal of the wire and flushing, it was positioned in the ascending aorta just above the aortic valve. Three milliliters of blood were gently aspirated from each catheter and discarded. Then, simultaneously, 2-ml blood samples for the serotonin assay were collected from each catheter by gentle aspiration into a plastic syringe. Previously, we have shown that the sampling of blood in this manner through a long catheter does not cause an artifactual increase in serotonin concentration.' All samples were collected at the beginning of the cardiac catheterization procedure before systemic heparin administration or the injection of angiographic contrast media. After collection of the samples, hemodynamic measurements, left ventriculography, and coronary arteriography were performed. All samples were collected between 8:00 AM and 2:00 PM. Nitroglycerin was not administered routinely before coronary arteriography. To assess the reproducibility of the sampling methods, 18 randomly selected patients had duplicate aortic and coronary sinus samples obtained approximately 5 minutes after the first samples were collected. No patient developed angina or important hemodynamic alterations between the collection of the duplicate samples. The first set of samples collected was used for the calculation of the coronary sinus and aortic serotonin differences described later.
Sample Preparation and Serotonin Assay
Samples were prepared for assay according to the method of Benedict et al. 4 Briefly, immediately after aspiration, 2 ml whole blood was placed in a plastic tube containing 90 ,gl 4% ethylenediamine tetraacetic acid and 0. 15% imipramine. Four micrograms of prostacyclin was added to this mixture. Because prostacyclin is unstable in acidic solutions, a stock solution was made in 70% acetonitrile solution and diluted when necessary in phosphate buffer, pH 8.0, containing 5% albumin. This mixture was spun in a refrigerated centrifuge at 120g for 10 minutes at 100 C to obtain platelet-rich plasma. The platelet-rich plasma was transferred to another tube containing a 9:1 sucrose:albumin "cushion" at the bottom. This was spun in a refrigerated centrifuge at 3,000g to obtain platelet-poor plasma, which was stored at -100 C for subsequent assay. Serotonin was measured by the radioenzymatic assay method of Hussain and Sole,13 modified by Benedict et a14 as previously described. Results of the assay are expressed in nanograms per milliliter. The absolute sensitivity of this assay is 1.2 pg. The interassay coefficient of variation is 3.75% as determined by an analysis of plasma samples repeated six times during 6 days with six different assays. distal to the area of stenosis was delayed compared with that in the other coronary vessels.
Data and Statistical Analyses
Changes in serotonin concentrations across the coronary bed were assessed by determining the difference between the coronary sinus and aortic serotonin concentrations. In this format, a positive number reflects a coronary sinus serotonin concentration higher than the aortic value. All data are expressed as the mean ± SD. Differences between groups were evaluated by a t test for unpaired data or a nonparametric analysis (Mann-Whitney) if the variances of the two groups were dissimilar (Bartlett's test). A least squares linear regression analysis was used for the comparison of the duplicate aortic and coronary sinus samples. Ap value less than 0.05 was considered significant.
Results
Validation of Sampling Methods
Platelet activation and serotonin release could occur during the aspiration of blood samples through long catheters. This could lead to an artifactual increase in the serotonin concentration or considerable variability of the measured values. Having established previously that the careful collection of blood samples through long catheters does not cause an artifactual change in serotonin concentration,12 we evaluated the reproducibility of our sampling methods in the present study by obtaining duplicate aortic and coronary sinus samples. The correlation between the aortic samples was excellent (r = 0.94, p < 0.001, SEE = 5.14 ng/ml) ( Figure 1,  left panel) . Likewise, a significant correlation existed between the duplicate coronary sinus samples (r= 0.74, p <0.001), although the standard error of the estimate was larger (12.3 ng/ml). This occurred because three values varied widely between the two determinations ( Figure 1, right panel) 
Aortic and Coronary Sinus Serotonin Concentrations
The aortic and coronary sinus serotonin concentrations were compared in the patients with and without significant coronary artery disease ( Figure  2 ). In those without coronary disease, the mean aortic serotonin concentration was 14.6 ± 10.49 ng/ ml, and the mean coronary sinus serotonin concentration was 9.0 ±7.36 ng/ml (p =0.075). Most of the individual patients in this group had a minimal variation in serotonin concentration across the coronary bed, and the remainder had substantial decreases. In the patients with significant coronary artery disease, the mean aortic serotonin concentration was 13.5 ± 13.62 ng/ml; this value was not different from the mean coronary sinus concentration of 13.4 ± 13.11 ng/ml. Neither the mean aortic nor coronary sinus concentration in the group with significant coronary artery disease was different from the corresponding value in the patients without coronary artery disease. However, in the group with coronary artery disease, several individual patients had substantial increases in the coronary sinus serotonin concentration, a pattern that was not observed in the subjects without significant coronary artery disease.
Coronary Sinus and Aortic Serotonin
Concentration Difference
To characterize the change in serotonin concentration across the coronary bed, the coronary sinus and aortic serotonin concentration difference was determined for each patient (Figure 3) . In those without significant coronary artery disease, the concentration difference was -5.6± 10.32 ng/ml, and in those with coronary artery disease, it was 0.6 ± 6.62 ng/ml (p<0.05). Although there was considerable overlap between the two groups, the highest coro- ng/ml. This was significantly higher (p<0.02) than the concentration difference in patients with simple lesion morphologies (-1.9 ± 6.61 ng/ml) (Figure 4) .
There was no clear association between the presence of unstable symptoms and coronary sinus and aortic serotonin concentration differences. In the patients with significant coronary artery disease, 19 had unstable symptoms. The mean concentration difference in these patients was -1.2±6.06 ng/ml; this value was not significantly different from the value in patients with stable, but severe, limiting angina (1.3±7.05 ng/ml). However, irrespective of the presence or absence of unstable symptoms, the classification of lesion morphology appeared to be important. Ten patients had complex lesion morphologies and stable, though, very limiting angina. The relation of smoking to the coronary sinus and aortic serotonin concentration difference was evaluated in the groups with and without coronary artery disease. In those without coronary artery disease, the concentration difference was -9.0± 13.8 ng/ml in smokers compared with -2.7±2.2 ng/ml in the nonsmokers (NS). Similarly, there was no difference in the concentration difference in those with coronary artery disease (-0.7±5.4 in smokers vs. 0.3±7.8 ng/ml in nonsmokers).
Use ofAspirin and Other Medications
Because it was not possible to withdraw or precisely control all medications before the collection of the samples, the frequency of use of certain medications in the groups with different coronary morphologies was determined. There were no differences in the use of calcium antagonists or ,Bblockers between the groups (Table 2) . A smaller percentage of the patients without coronary artery disease were receiving nitrates, but this was not statistically significant (p = 0.08). However, a greater percentage of the patients with simple lesion morphologies (67%) were receiving aspirin compared with the other two groups (p = 0.008). To determine whether or not aspirin consumption, in general, caused a detectable change in serotonin concentration, aortic and coronary sinus serotonin values, as well as the coronary sinus and aortic serotonin concentration difference, were compared in patients who were and were not receiving aspirin (Table 3) . There were no differences in either the mean aortic or coronary sinus serotonin concentrations between the patients who were and were not receiving aspirin. These values were compared separately in those with and without coronary disease, and no detectable differences could be found between the groups. When patients with and without coronary artery disease were considered together, those taking aspirin (n = 25) had a lower concentration difference than those not taking aspirin (n =27). However, when only those with coronary artery disease were considered, there was no difference in the concentration difference between those receiving and not receiving aspirin (Table 3) . A meaningful subgroup analysis of patients with simple and complex lesions who were and were not receiving aspirin was not possible because there were too few patients in some of the groups.
Discussion
Numerous experimental and clinical findings have led to speculation regarding the mechanisms that cause unstable angina and their link to the pathogenesis of acute myocardial infarction. 1-3,20-22Hemo-dynamic, rheologic, and vasomotor stresses may damage atherosclerotic plaques, and such damage may initiate the local release of vasoconstrictor and thrombogenic substances or an imbalance between these substances and intrinsic vasodilating and antithrombotic mediators. In some patients, these interactions may cause the development of an intraluminal thrombus or coronary artery constriction. Evolution of this process to complete coronary occlusion may result in worsening angina or the onset of myocardial infarction.
Role of Serotonin
Considerable experimental evidence indicates that serotonin may have a role in this process,4,5,7-9,23 and this concept has been enhanced by recent clinical observations.24 It has been shown that aliquots of coronary sinus plasma from patients with coronary artery disease cause constriction of isolated canine coronary artery rings, whereas systemic arterial and venous samples from the same patient and coronary sinus samples from patients without coronary artery disease do not.24 Many pharmacologic interventions were tested against this action, and only a serotonin receptor antagonist prevented constriction of the coronary artery rings. 24 Although serotonin was not measured directly, these bioassay data indicated that serotonin was important. Moreover, these data suggest that the amount of serotonin released into the coronary sinus is sufficient to have physiologically demonstrable effects.
In this study, we have shown that 23% of the patients with coronary artery disease have a coronary sinus and aortic serotonin concentration difference that is greater than the highest value in those without coronary artery disease. The appreciation of transcardiac alterations in serotonin concentration could be affected by several technical factors related to the sampling methods. For example, a greater variability was noted in the serotonin concentration values obtained from the coronary sinus. This occurred despite a stable catheter position within the coronary sinus and may reflect the incomplete mixing of blood from the various tributaries entering the coronary sinus. Furthermore, it is possible that serotonin is released into the coronary sinus sporadically as platelets aggregate. This coupled with incomplete mixing could result in a failure to detect release of serotonin into the coronary circulation and contribute to an underestimation of the number of patients actually having serotonin production. A few patients had extremely negative coronary sinus and aortic serotonin concentration differences. Whether or not this is related to the variability of the sampling process, the dilution of serotonin in the coronary effluent, or the actual degradation of serbtonin as it passes through the myocardial capillary bed cannot be determined by this study.
Relation of Serotonin to Lesion Morphology
Previous studies have shown that certain coronary lesion morphologies occur more often in patients with unstable angina and acute myocardial infarction. Specifically, eccentric coronary artery stenoses with narrow necks, overhanging edges, or scalloped surfaces, and stenoses associated with intraluminal filling defects have been noted with increased frequency. 14 
Effect of Smoking and Medications
There was no obvious relation between smoking and the serotonin values measured. The concurrent administration of aspirin and other medications having platelet effects is a confounding variable in the interpretation of these data. Because approximately one half of the patients with coronary artery disease had unstable symptoms, the withdrawal of all medications before the study was not possible. There were no differences in the frequency of use of calcium antagonists and fl-blockers between the groups, but a greater percentage of patients with simple coronary lesion morphology were receiving aspirin. The relation of this observation to the lower coronary sinus and aortic serotonin concentration differences in this group is uncertain. The aortic and coronary sinus serotonin concentrations as well as the coronary sinus and aortic serotonin concentration difference were compared in those patients who were and were not receiving aspirin to determine whether or not aspirin caused major changes in the serotonin concentrations. Although no detectable changes could be shown in the various subgroups, it is still possible that aspirin could have some physiologically important effect on the serotonin release from platelets. Because all patients received the same premedications at approximately the same time before the study, it is unlikely that these would have altered the results substantially even though antihistamines could possibly alter serotonin production. Although some of these medications may affect the serotonin concentrations, the results of this study will more closely approximate the clinical situation because most patients with coronary artery disease will be receiving medications a long-term basis.
Clinical Implications
The present study suggests that serotonin release occurs in some patients with important coronary artery disease, especially those with complex coronary lesions that could act as a nidus for platelet activation. Although serotonin release was not detected in every patient, it is possible that the concentration of serotonin was elevated locally around the stenotic site and not detected in the coronary sinus. The finding of an elevated coronary sinus and aortic serotonin concentration difference in some patients with coronary artery disease and an association between these values and complex coronary artery morphology does not prove that the increased transcardiac serotonin concentrations detected are important physiologically. Further studies are necessary to define the role of serotonin in acute ischemic syndromes, but these data are consistent with a hypothesis that serotonin may play an important pathophysiologic role in sustaining certain ischemic heart syndromes in some patients.
